Paper Details

  1. Home
  2. Paper Details

Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial.

Author: , BoyerMichelle, DobberJohan A, DompelingEllen C, DuboisJulie, EversLudo M, HoogendoornMels, HoutenbosIlse, IdinkCecile A M, IssaDjamila E, KaterArnon P, KerstingSabina, KoeneHarry R, LevengaHenriette, LevinMark-David, MellinkClemens, MobasherMehrdad, NasserinejadKazem, PosthumaEduardus F M, SchreursJohn, TerpstraWim E, TickLidwine W, ToninoSanne H, VeelkenHendrik, VeldersGerjo A, VisserHein P J, de BoerFransien, van GelderMichel, van ZaanenHenk C T, van der Kevie-KersemaekersAnne-Marie F, van der KliftMarjolein, van der SpekEllen, van der StraatenHanneke M

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study aims to determine the activity and safety of 12 cycles of venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated patients with chronic lymphocytic leukaemia who were unfit for fludarabine-based treatment, and whether this could be guided by minimal residual disease status.
Paper Details　
Original Abstract of the Article :
Fixed-duration 12 cycles of venetoclax plus obinutuzumab is established as first-line treatment for patients with chronic lymphocytic leukaemia. We aimed to determine the activity and safety of 12 cycles of venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously unt...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S2352-3026(22)00034-5

データ提供：米国国立医学図書館（NLM）

New Horizons in the Desert of Chronic Lymphocytic Leukemia

Chronic lymphocytic leukemia (CLL) is a challenging disease, like a vast and unpredictable desert. This research explores the effectiveness of venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated patients with CLL. Imagine this research as a team of explorers, charting a new course through the desert of CLL, seeking a more effective and personalized approach to treatment.

A More Targeted Approach to Treatment

The study found that 12 cycles of venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab showed promising activity and safety for patients with CLL who were unfit for fludarabine-based treatment. This is like discovering a new oasis in the CLL desert, offering a potentially effective treatment option for a specific group of patients. The researchers are investigating whether minimal residual disease status can guide the use of consolidation therapy.

A Brighter Future in the CLL Desert

This research holds promise for improving outcomes for patients with CLL, offering a more targeted and personalized approach to treatment. This is like finding a more reliable path through the CLL desert, potentially leading to longer and healthier lives for patients. The researchers’ efforts to refine this approach based on minimal residual disease status could lead to more effective and personalized treatment strategies.

Dr. Camel's Conclusion

This research offers a glimmer of hope in the desert of CLL, showcasing a new and potentially promising approach to treatment. The use of venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab represents a significant step forward in the fight against CLL, offering a more personalized and targeted approach to treatment, like finding a new oasis in the heart of this challenging landscape.

Date :
  1. Date Completed 2022-03-07
  2. Date Revised 2022-03-07
Further Info :

Pubmed ID

35240075

DOI: Digital Object Identifier

10.1016/S2352-3026(22)00034-5

Related Literature

Article Analysis
・Side Effects of venetoclax
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.